These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37516008)

  • 1. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
    Nagasaka M; Brazel D; Baca Y; Xiu J; Al-Hallak MN; Kim C; Nieva J; Swensen JJ; Spetzler D; Korn WM; Socinski MA; Raez LE; Halmos B; Ou SI
    Transl Oncol; 2023 Oct; 36():101744. PubMed ID: 37516008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
    Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
    Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
    Nagasaka M; Zhang SS; Baca Y; Xiu J; Nieva J; Vanderwalde A; Swensen JJ; Spetzler D; Korn WM; Raez LE; Liu SV; Ou SI
    BMC Cancer; 2023 Oct; 23(1):1000. PubMed ID: 37853341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
    Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
    Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
    Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
    Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
    Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
    J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
    Gu L; Ji W; Xu Y; Han Y; Jian H
    Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics and diagnostic methods of
    Feng J; Li Y; Wei B; Guo L; Li W; Xia Q; Zhao C; Zheng J; Zhao J; Sun R; Guo Y; Brcic L; Hakozaki T; Ying J; Ma J
    Transl Lung Cancer Res; 2022 Apr; 11(4):617-631. PubMed ID: 35529790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
    Skálová A; Ptáková N; Santana T; Agaimy A; Ihrler S; Uro-Coste E; Thompson LDR; Bishop JA; Baněčkova M; Rupp NJ; Morbini P; de Sanctis S; Schiavo-Lena M; Vanecek T; Michal M; Leivo I
    Am J Surg Pathol; 2019 Oct; 43(10):1303-1313. PubMed ID: 31162284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalog of 5' fusion partners in
    Ou SI; Zhu VW
    JTO Clin Res Rep; 2020 Jun; 1(2):100037. PubMed ID: 34589933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.